10.20.26 -- Targeting p27 To 'Let Biology Do The Work' With Stacy Blain, CEO, Concarlo Therapeutics

Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.

Physiologically based pharmacokinetic modeling is a powerful tool for clinical trial design that can be leveraged alongside early development experiments to reduce costs and accelerate timelines.

Accelerate drug discovery by leveraging transiently transfected assay-ready cells. This method improves assay sensitivity and reduces variability for GPCRs.

Personalized cancer vaccines are advancing quickly, but effective delivery remains a major hurdle. Learn how mRNA and lipid nanoparticle design influence targeting, endosomal escape, and repeat dosing.

Even limited daily pipetting can increase the risk of repetitive strain injuries. Explore ways to improve posture, equipment selection, and workflow design while supporting long-term productivity.

See how to reconstitute lyophilized proteins with greater consistency, from selecting a diluent and calculating concentration to mixing gently, preventing aggregation, and maintaining stability.

Hidden packaging and drug interactions pose real risks. A collaborative knowledge base helps scientists unify data, improve decisions, and advance safer development through accessible E&L insights.

SDD scale-up introduces risks that threaten bioavailability, stability, and manufacturability. Examine a model-based framework for managing those risks from early feasibility through production.